Release Date: 2024-01-19

Medical and Surgical Approaches in Cerebral Palsy

Mahmut Surmeli (Author), Ramazan Yildiz (Author)

Release Date: 2024-01-19

Cerebral palsy (CP) is a neurological condition characterized by permanent motor dysfunction caused by a developmental brain injury. Treatment of CP focuses on managing symptoms and improving patients’ quality of life. Medical and surgical treatment approaches are tailored to the individual needs of patients. Pharmacological treatments are used to reduce spasticity, control pain, manage seizures, [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inPhysiotherapy and Rehabilitation for Cerebral Palsy
    First Page125
    Last Page141
    DOIhttps://doi.org/10.69860/nobel.9786053358794.7
    LanguageENG
    Page Count17
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Cerebral palsy (CP) is a neurological condition characterized by permanent motor dysfunction caused by a developmental brain injury. Treatment of CP focuses on managing symptoms and improving patients’ quality of life. Medical and surgical treatment approaches are tailored to the individual needs of patients. Pharmacological treatments are used to reduce spasticity, control pain, manage seizures, and treat other associated symptoms. Oral medications frequently used in SP are benzodiazepines, baclofen, sodium dantrolene, tizanidine, and other alpha-2 adrenergic agonists, gabapentin and tiagabine. Botulinum toxin (BoNT), which is one of the intramuscular medications, has an important place among pharmacological applications in the treatment of spasticity. Phenol and alcohol injections are invasive treatment methods used to manage spasticity in cerebral palsy. These are agents that create selective denervation by injecting into motor nerves or muscles. Baclofen works as an agonist of gamma-aminobutyric acid (GABA) receptors and exerts inhibitory effects on the central nervous system (CNS). Intrathecal baclofen is the preferred method when the oral form is insufficient or serious side effects occur. Pharmacological approaches to treating cerebral palsy are customized to the individual’s specific symptoms and needs. It gives the most effective results when used together with other treatment methods such as drug treatments, physiotherapy, occupational therapy and surgical interventions. Treatment plans require regular monitoring and adjustment and are managed through a multidisciplinary approach. Surgical interventions can be used in the treatment of cerebral palsy (CP) to reduce spasticity, correct deformities such as scoliosis and hip dislocation, and increase the functional abilities of patients. Surgical options are determined based on the patient’s specific needs and symptoms. Treatment of cerebral palsy requires a multidisciplinary approach. Medical and surgical treatments are aimed at managing patients’ symptoms, increasing their functional abilities, and improving their quality of life. Treatment plans are customized to each patient’s individual needs and require ongoing monitoring. With the development of new treatment methods, more effective and innovative approaches are being adopted in the management of cerebral palsy.

    Mahmut Surmeli (Author)
    Asst. Prof. Dr., Tokat Gaziosmanpasa University
    https://orcid.org/0000-0002-5661-922X
    3In 2013, he graduated as a physiotherapist from the Physical Therapy Undergraduate Program. In 2018, he obtained his master’s degree in the Department of Physical Therapy and Rehabilitation, and in 2023, he completed his doctoral studies. Alongside clinical work in Cardiopulmonary Rehabilitation and Rehabilitation of Phlebological Disorders, he also conducts preclinical research on animal models. He currently works as an assistant professor in the Department of Physiotherapy and Rehabilitation at Tokat Gaziosmanpaşa University.

    Ramazan Yildiz (Author)
    Asst. Prof. Dr., Erzurum Technical University
    https://orcid.org/0000-0002-8007-7854
    3He completed her bachelor degree at Kırıkkale University. He completed her Master of Science (2017) and PhD (2022) in the Department of Physical Therapy and Rehabilitation at the Gazi University. Her field of master’s education is " Children with Minor Neurological Dysfunction". He worked in Gazi University as a research assistant between 2016 and 2022. Now, he is working at Erzurum Technical University as an Assistant Professor. He has focused on early intervention and early diagnosis of infants at risk. He has specialized in early intervention in academic activities such as book chapters, academic publications, and congress presentations. Additionally, his other area of ​​interest is adolescent idiopathic scoliosis and he is an ISST Schroth therapist. He has 10 years of experience in the clinic and he teaches pediatrics at the undergraduate levels. His primary research focus is on "children with cerebral palsy", “early intervention”, “premature infants” and ‘’adolescent idiopathic scoliosis’’

    • Albright, A. L. (1995). “Spastic cerebral palsy: Approaches to drug treatment.” CNS drugs 4(1): 17-27.

    • Albright, A. L. (2003). “Neurosurgical treatment of spasticity and other pediatric movement disorders.” Journal of child neurology 18(1_suppl): S67-S78.

    • Allen Jr, B. and R. Ferguson (1982). “L-rod instrumentation for scoliosis in cerebral palsy.” Journal of pediatric orthopedics 2(1): 87-96

    • Allen Jr, B. L. and R. L. FERGUSON (1982). “The Galveston technique for L rod instrumentation of the scoliotic spine.” Spine 7(3): 276-284

    • Andrew, K. L., et al. (2004). “Cerebral palsy.” The Lancet 363(9421): 1619-1631. Bakheit, A., et al. (2001). “Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity.” Developmental medicine and child neurology 43(4): 234-238.

    • Bohannon, R. W. and M. B. Smith (1987). “Interrater reliability of a modified Ashworth scale of muscle spasticity.” Physical Therapy 67(2): 206-20

    • Boyd, R. and H. K. Graham (1997). “Botulinum toxin A in the management of children with cerebral palsy: indications and outcome.” European Journal of Neurology 4(Suppl. 2): S15-S

    • Boyd, R. N. and H. K. Graham (1999). “Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy.” European Journal of Neurology 6: s23-s35.

    • Boyd, R. N., et al. (1999). “Medium‐term response characterisation and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy.” European Journal of Neurology 6: s37-s45

    • Davidoff, R. A. (1985). “Antispasticity drugs: mechanisms of action.” Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 17(2): 107-116.

    • Dias, R. C., et al. (1997). “Revision spine surgery in children with cerebral palsy.” Clinical Spine Surgery 10(2): 132-14

    • Golan, J. D., et al. (2007). “Spinal deformities following selective dorsal rhizotomy.” Journal of Neurosurgery: Pediatrics 106(6): 441-449.

    • Goldstein, E. M. (2001). “Spasticity management: an overview.” Journal of child neurology 16(1): 16-2

    • Gracies, J. M. (2004). “Physiological effects of botulinum toxin in spasticity.” Movement disorders: official journal of the Movement Disorder Society 19(S8): S120-S128.

    • Graham, H. K., et al. (2000). “Recommendations for the use of botulinum toxin type A in the management of cerebral palsy.” Gait & posture 11(1): 67-79

    • Guillaume, D., et al. (2005). “A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity.” Archives of physical medicine and rehabilitation 86(11): 2165-217

    • Hägglund, G., et al. (2005). “Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care programme and new techniques to reduce spasticity.” Journal of Pediatric Orthopaedics B 14(4): 269-273

    • Herring, J. A. (2002). “Disorders of the brain.” Tachjian’s pediatric orthopaedics

    • Hodgkinson, I., et al. (2001). “Hip pain in 234 non-ambulatory adolescents and young adults with cerebral palsy: a cross-sectional multicentre study.” Developmental medicine and child neurology 43(12): 806-808

    • Jevsevar, D. S. and L. I. Karlin (1993). “The relationship between preoperative nutritional status and complications after an operation for scoliosis in patients who have cerebral palsy.” JBJS 75(6): 880-884.

    • Kolaski, K. and L. R. Logan (2008). “Intrathecal baclofen in cerebral palsy: a decade of treatment outcomes.” Journal of Pediatric Rehabilitation Medicine 1(1): 3-32

    • Koman, L. A., et al. (2003). “Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin.” Pediatric Drugs 5: 11-23.

    • Krach, L. E. (2001). “Pharmacotherapy of spasticity: oral medications and intrathecal baclofen.” Journal of child neurology 16(1): 31-36

    • Krigger, K. W. (2006). “Cerebral palsy: an overview.” American family physician 73(1): 91-100.

    • Langerak, N. G., et al. (2009). “Incidence of spinal abnormalities in patients with spastic diplegia 17 to 26 years after selective dorsal rhizotomy.” Child’s Nervous System 25: 1593-1603.

    • Lipton, G. E., et al. (1999). “Factors predicting postoperative complications following spinal fusions in children with cerebral palsy.” Clinical Spine Surgery 12(3): 197- 205.

    • Luque, E. R. (1982). “Segmental spinal instrumentation for correction of scoliosis.” Clinical Orthopaedics and Related Research (1976-2007) 163: 192-198.

    • McCarthy, R. E. (1999). “Management of neuromuscular scoliosis.” Orthopedic Clinics of North America 30(3): 435-449

    • Molenaers, G., et al. (1999). “Botulinum toxin type A treatment of cerebral palsy: an integrated approach.” European Journal of Neurology 6: s51-s57

    • Murphy, N. A., et al. (2002). “Intrathecal baclofen therapy in children with cerebral palsy: efficacy and complications.” Archives of physical medicine and rehabilitation 83(12): 1721-1725.

    • O’Brien, D. F. and T. S. Park (2006). “A review of orthopedic surgeries after selective dorsal rhizotomy.” Neurosurgical focus 21(2): E2

    • O’Brien, D. F., et al. (2004). “Effect of selective dorsal rhizotomy on need for orthopedic surgery for spastic quadriplegic cerebral palsy: long-term outcome analysis in relation to age.” Journal of Neurosurgery: Pediatrics 101(2): 59-63

    • On, A. Y., et al. (1999). “Mechanisms of Action of Phenol Block and Botulinus Toxin Type a in Relieving Spasticity: Electrophysiologic Investigation and Follow-Up: 1.” American journal of physical medicine & rehabilitation 78(4): 344-349

    • Papavasiliou, A. S. (2009). “Management of motor problems in cerebral palsy: a critical update for the clinician.” european journal of paediatric neurology 13(5): 387-396

    • Papavasiliou, A. S., et al. (2006). “Evaluation of a multimodal management of prematurity-related spasticity.” Pediatric neurology 35(6): 400-407

    • Park, T. S. and J. M. Johnston (2006). “Surgical techniques of selective dorsal rhizotomy for spastic cerebral palsy.” Neurosurgical focus

    • Samilson, R. L., et al. (1967). “Results and complications of adductor tenotomy and obturator neurectomy in cerebral palsy.” Clinical Orthopaedics and Related Research® 54: 61-74.

    • Scheinberg, A., et al. (2006). “Oral baclofen in children with cerebral palsy: A double‐blind cross‐over pilot study.” Journal of paediatrics and child health 42(11): 715-720

    • Schmale, G. A., et al. (2006). “High reoperation rates after early treatment of the subluxating hip in children with spastic cerebral palsy.” Journal of Pediatric Orthopaedics 26(5): 617-623

    • Scholtes, V. A., et al. (2007). “Effect of multilevel botulinum toxin a and comprehensiverehabilitation on gait in cerebral palsy.” Pediatric neurology 36(1): 30-39

    • Shore, B. J., et al. (2012). “Adductor surgery to prevent hip displacement in children with cerebral palsy: the predictive role of the Gross Motor Function Classification System.” JBJS 94(4): 326-334.

    • Sussman, M. D., et al. (1996). “Posterior instrumentation and fusion of the thoracolumbar spine for treatment of neuromuscular scoliosis.” Journal of Pediatric Orthopaedics 16(3): 304-313

    • SWANK, S. M., et al. (1989). “Spine fusion in cerebral palsy with L-rod segmental spinal instrumentation: a comparison of single and two-stage combined approach with Zielke instrumentation.” Spine 14(7): 750-759.

    • Tilton, A. H. (2004). Management of spasticity in children with cerebral palsy. Seminars in Pediatric neurolog

    • Tsirikos, A. I. (2010). “Development and treatment of spinal deformity in patients with cerebral palsy.” Indian journal of orthopaedics 44(2): 148-158.

    • Tsirikos, A. I., et al. (2008). “Surgical correction of scoliosis in pediatric patients with cerebral palsy using the unit rod instrumentation.” Spine 33(10): 1133-1140

    • Tsirikos, A. I. and P. Spielmann (2007). “Spinal deformity in paediatric patients with cerebral palsy.” Current Orthopaedics 21(2): 122-134.

    • Verrotti, A., et al. (2006). “Pharmacotherapy of spasticity in children with cerebral palsy.” Pediatric neurology 34(1): 1-6

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!